BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis - Top-Institutions - MDSpire

BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis

  • By

  • Thomas Silfverberg

  • Christina Zjukovskaja

  • Yassine Noui

  • Kristina Carlson

  • Joachim Burman

  • August 26, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, Sweden

    Key Differentiators

    • Neurology
    • Hematology
    • Stem Cell Transplantation

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Neurology
    • Hematology
    • Stem Cell Transplantation

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, California

    Key Differentiators

    • Neurology
    • Hematology
    • Stem Cell Transplantation

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Neurology
    • Hematology
    • Stem Cell Transplantation

  • #5

    University College London (UCL)
    University College London (UCL)

    London, England

    Key Differentiators

    • Neurology
    • Hematology
    • Stem Cell Transplantation

Original Source(s)

BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis

  • by Thomas Silfverberg, Christina Zjukovskaja, Yassine Noui, Kristina Carlson, Joachim Burman

  • August 26, 2024

Related Content

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations

CAR-T cell therapy embarks on autoimmune disease